Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.

Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab

After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.

Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis

Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.

Will Merck (MRK) Succeed in Beating Q4 Earnings Expectations?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.

Best Growth Stocks to Buy for February 1st

CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 1, 2022

Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel

Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.

Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?

Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.

Pfizer (PFE) Lorviqua Gets EU Nod for First-Line Lung Cancer

The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.

Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema

While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.

AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery

AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.

Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings?

Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.

Best Growth Stocks to Buy for January 31st

PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2022

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and J&J

Pfizer, BioNTech, Moderna and J&J are included in this analyst blog.

Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid

Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.

Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use

Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.

Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.

Kinjel Shah headshot

Pharma Stock Roundup: J&J Q4 Earnings, FDA's Rejection of PFE, MRK Pipeline Drugs

J&J (JNJ) reports mixed fourth-quarter results. FDA issues CRL to Merck (MRK) and Pfizer's (PFE) pipeline candidates. FDA approves AbbVie's (ABBV) Skyrizi for a second indication.

Best Growth Stocks to Buy for January 28th

CROX, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 28, 2022

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study

Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.

Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab

Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.

Best Growth Stocks to Buy for January 27th

TOL, PFE, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 27, 2022

Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?

Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.

The Zacks Analyst Blog Highlights: Mastercard Inc., Pfizer Inc. and Citigroup Inc

Mastercard Inc., Pfizer Inc. and Citigroup Inc are included in this blog.

The Zacks Analyst Blog Highlights: Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck

Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck are included in this blog.